AI assistant
Marksans Pharma Ltd. — Earnings Release 2020
Jun 2, 2020
62142_rns_2020-06-02_7ae353fe-fd8b-4ca4-a045-6479a6d65015.pdf
Earnings Release
Open in viewerOpens in your device viewer
•• Marksans Pharma Ltd.
BSELimited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 40000l. Scrip Code: 524404
National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS
Enclosed herewith kindly fi d a News Release dated 2[nd] June, 2020 of the Company.
Yours faithfully, For Marksans Pharma Limited
Harshavardhan Panigrahi Company Secretary
Marksans Pharma Ltd.;
~ 1~~FI.O(0)"GRAND.EUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara n en , Mumbal - 400 053 • Tel.: +91 224001 2000 • E-mail: [email protected]~ www.marksanspharma.com
==> picture [343 x 60] intentionally omitted <==
FY20 Revenue at Rs. 1,134.5 Cr.; growth of 12.9%
EBITDA at Rs. 192.6 Cr., growth of 40.8%
Mumbai, June 2[nd] , 2020 – Marksans Pharma Ltd (NSE: MARKSANS; BSE Code: 524404), one of the fastest growing pharmaceutical companies in India today announced financial results for the fourth quarter and year ended March 31[st] , 2020.
Financial Highlights - Consolidated Financial Overview:
| In Rs. Cr. | YoY | YoY% | YoY Growth (%) |
YoY% | ||||
|---|---|---|---|---|---|---|---|---|
| FY20 | FY19 | Growth | (Constant | Q4FY20 | Q4FY19 | (Constant currency) |
||
| (%) | currency) | |||||||
| Total Revenue | 1,134.5 | 1,004.7 | 12.9% | 15.8% | 335.4 | 257.1 | 30.4% | 33.9% |
| EBITDA | 192.6 | 136.8 | 40.8% | 41.1% | 69.2 | 25.4 | 172.8% | 173.4% |
| EBITDAMargin% | 17.0% | 13.6% | 336 bps | 297 bps | 20.6% | 9.9% | 1,077 bps | 1,028 bps |
| PAT | 120.8 | 80.4 | 50.1% | 50.5% | 42.7 | 9.9 | 333.8% | 334.8% |
| PATMargin% | 10.6% | 8.0% | 264 bps | 239 bps | 12.7% | 3.8% | 891 bps | 861 bps |
Consolidated FY20 (Y-o-Y)
Overall business grew by 15.8% in constant currency basis in FY20 as compared to FY19
-
Total Revenue was Rs. 1,134.5 Cr. as compared to Rs. 1,004.7Cr. in FY19, an increase of 12.9%
-
EBITDA was Rs. 192.6 Cr. as compared to Rs. 136.8 Cr. in FY19, a growth of 40.8% EBITDA Margin stood at 17.0% for FY20 as against 13.6% in FY19
-
PAT stood at Rs. 120.8 Cr. as compared to Rs. 80.4 Cr. in FY19, an increase of 50.1%
Consolidated Q4 FY20 (Y-o-Y)
Overall business grew by 33.9% in constant currency basis in Q4 FY20 as compared to Q4 FY19
-
Total Revenue was Rs. 335.4 Cr as compared to Rs. 257.1 Cr in Q4 FY19, an increase of 30.4% EBITDA was Rs. 69.2 Cr. as compared to Rs. 25.4 Cr. in Q4 FY19, an increase of 172.8% EBITDA Margin stood at 20.6% for Q4 FY20 as against 9.9% in Q4 FY19
-
PAT stood at Rs. 42.7 Cr. as compared to Rs. 9.9 Cr. in Q4 FY19, a growth of 333.8%
Commenting on the performance Mark Saldanha, Managing Director of the Company said ““I am
extremely delighted to share with you the strong performance in this fiscal despite the lockdown due to the COVID pandemic at the end of March. Revenue for the year expanded by ~13% and EBITDA by ~41%. We also received EIR from the US FDA for Time Cap Laboratories located at Farmingdale, New York, USA. This positions us favorably to expand our reach in US market.
On the financial front we became a zero-debt company with cash of Rs 94 crore at the end of this fiscal. The outlook for FY21 looks positive and we expect the growth momentum to continue.”
Business Performance
Revenue by Market:
| in Rs. Cr. | FY20 | FY19 | YoY Growth (%) |
YoY% Constant Currency |
Mix (FY20) % |
|---|---|---|---|---|---|
| Europe, UK – Formulations | 510.0 | 413.0 | 23.5% | 27.6% | 44.9% |
| US & North America – Formulations | 436.4 | 411.5 | 6.1% | 6.3% | 38.5% |
| Australia & NZ – Formulations | 140.7 | 119.9 | 17.3% | 26.6% | 12.4% |
| Rest of World(ROW) | 47.4 | 60.3 | -21.3% | -21.1% | 4.2% |
| Consolidated Revenue from operations | 1,134.5 | 1,004.7 | 12.9% | 15.8% | 100.0% |
Business Highlights
-
Company achieved revenue of Rs. 510.0 cr. from Europe, UK: Formulation business in FY20 as compared to Rs. 413.0 cr. achieved during last year same period registering a growth of 23.5%
-
US & North America Formulation business reported growth of 6.1% to Rs 436.4 cr. in FY20 Australia & NZ Formulation business revenue was at Rs. 140.7 cr. in FY20, registering growth of 17.3% YoY
-
Rest of World Formulation business was Rs. 47.4 cr. in FY20
About Marksans Pharma Ltd
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.
For details, feel free to contact:
Investor Relations Team at Marksans Pharma Registered Office 11th Floor, "GRANDEUR” Jitendra Sharma, CFO Off Veera Desai Extension Road Marksans Pharma Ltd Oshiwara, Andheri West Tel: +91 022 40012000 Mumbai, Maharashtra, 400 053 [email protected] Telephone: +91 224001 2000 Fax: +91 224001 2011 Dikshita Jain CIN: L24110MH1992PLC066364 Christensen Investor Relations ISIN: INE750C01026 Tel : +91 22 4215 0210 NSE Code: MARKSANS [email protected] BSE CODE: 524404 Website: http://www.marksanspharma.com